Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
EVAX Stock Chart & Stats
$6.13
-$0.02(-2.40%)
At close: 4:00 PM EST
$6.13
-$0.02(-2.40%)
Day’s Range― - ―
52-Week Range$1.20 - $15.50
Previous CloseN/A
Volume99.85K
Average Volume (3M)3.27M
Market Cap
$37.20M
Enterprise Value$10.03M
Total Cash (Recent Filing)$14.75M
Total Debt (Recent Filing)$11.28M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Nov 11, 2025EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding6,316,572
10 Day Avg. Volume890,587
30 Day Avg. Volume3,266,736
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.75
Price to Sales (P/S)1.36
P/FCF Ratio-0.35
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue3.15
Enterprise Value/Gross Profit3.15
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$13.50Price Target Upside120.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial ProjectionsAnalyst maintains a Buy rating on EVAX and increases the 12-month price target to $16 per diluted ADS from $14.
Strategic PartnershipsMerck's option exercise extends EVAX's cash runway to 1H27, carrying EVAX through several milestones across its infectious disease and oncology programs.
Therapeutic AdvancementsSecond year data update strengthens EVX-01 profile, reinforcing promising efficacy and favorable safety profile of the combination therapy.
Bears Say
Evaxion Biotech News
EVAX FAQ
What was Evaxion Biotech’s price range in the past 12 months?
Evaxion Biotech lowest stock price was $1.20 and its highest was $15.50 in the past 12 months.
What is Evaxion Biotech’s market cap?
Evaxion Biotech’s market cap is $37.20M.
When is Evaxion Biotech’s upcoming earnings report date?
Evaxion Biotech’s upcoming earnings report date is Nov 11, 2025 which is in 13 days.
How were Evaxion Biotech’s earnings last quarter?
Evaxion Biotech released its earnings results on Aug 14, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.58 by $0.56.
Is Evaxion Biotech overvalued?
According to Wall Street analysts Evaxion Biotech’s price is currently Undervalued.
Does Evaxion Biotech pay dividends?
Evaxion Biotech does not currently pay dividends.
What is Evaxion Biotech’s EPS estimate?
Evaxion Biotech’s EPS estimate is 0.4.
How many shares outstanding does Evaxion Biotech have?
Evaxion Biotech has 6,316,572 shares outstanding.
What happened to Evaxion Biotech’s price movement after its last earnings report?
Evaxion Biotech reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.58. Following the earnings report the stock price went down -5.921%.
Which hedge fund is a major shareholder of Evaxion Biotech?
Currently, no hedge funds are holding shares in EVAX
Evaxion Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (120.23% Upside)
$13.50 (120.23% Upside)
Blogger Sentiment
Bullish
EVAX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 10.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 16.3%
Last 30 Days ▲ 16.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
Evaxion Biotech
Evaxion Biotech (EVAX) is a biotechnology company focused on the development of innovative immunotherapies and vaccines to combat infectious diseases and cancer. Utilizing its proprietary artificial intelligence platform, Evaxion identifies and develops novel therapeutic and preventive solutions aimed at enhancing the immune response. The company operates primarily in the biopharmaceutical sector, with core products and services centered around its AI-driven drug discovery and development processes.
EVAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in partnerships, financial stability, and R&D developments, particularly with the MSD partnership and a grant from the Gates Foundation. However, there are challenges due to regulatory and market uncertainties, and limited disclosure on clinical data was noted.View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
$13.50
▲(120.23% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.64% Other Institutional Investors
98.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---